Rovalpituzumab Tesirine (Rova-T), a First-in-Class Antibody-Drug Conjugate, Is Active in Patients with Recurrent Small-Cell Lung Cancer

TON Web Exclusives - Lung Cancer

Approximately 10% to 15% of all lung cancers are small-cell lung cancer (SCLC), an aggressive disease with relative 5-year survival rates ranging from 31% for stage I SCLC to 2% for metastatic SCLC.1 Because most patients with SCLC have metastatic disease at the time of diagnosis, surgical resection is rarely viable.

Cytotoxic chemotherapy and radiation are the most common forms of treatment for SCLC. Topotecan (Hycamtin), which was approved by the FDA in 1998 for second-line treatment of SCLC, remains the only treatment indicated for this use.

Delta-like protein 3 (DLL3) is a novel and actionable target for drug development in SCLC. DLL3 is an atypical inhibitor of the Notch ligand and is expressed on the surface of tumor cells in high-grade neuroendocrine carcinomas, including SCLC; approximately 85% of patients with SCLC express DLL3. In contrast, DLL3 is not expressed in healthy tissue or in cancer cells of nonneuroendocrine malignancies.2 Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody-drug conjugate directed against DLL3.

To assess the safety and activity of Rova-T in patients with SCLC who progressed after ≥1 previous regimens, a phase 1 open-label study was conducted at 10 cancer centers in the United States.2 Eligible patients had confirmed SCLC or large-cell neuroendocrine carcinoma (LCNEC) tumors with progressive measurable disease and had relapsed after treatment with 1 or 2 chemotherapy regimens, including a platinum-based combination. Patients with SCLC and evidence of brain metastases were ineligible for this study.

A total of 82 patients enrolled in the study, including 74 patients with SCLC and 8 patients with LCNEC. At the time of data analysis, median duration of follow-up was 3.9 months (range, 0.4-22.0 months). Patients with LCNEC were assessed for safety but were excluded from efficacy end point analyses.

Of 65 patients with SCLC who were assessable, 71% achieved disease control with Rova-T: 17% had confirmed objective response and 54% had stable disease. In 39 patients who provided biopsy samples, retrospective testing of DLL3 expression showed a relationship between DLL3 expression and response. Of the 29 patients who were found to be DLL3-high (DLL3 expression in ≥50% of cells), 35% had a confirmed objective response, and 90% achieved disease control with Rova-T. Of the 10 assessable patients who were DLL3-low, none achieved a confirmed objective response, and 6 of 10 experienced disease control. In the 68 patients treated with active dose levels of Rova-T, overall survival (OS) was 4.6 months (95% confidence interval [CI], 3.9-7.1 months). The 1-year OS rate was higher in DLL3-high patients, 32% (95% CI, 15%-49%), compared with 0% in DLL3-low patients.

Adverse events (AEs) of any grade were observed in 88% of patients with SCLC who received Rova-T, with grade ≥3 AEs noted in 38%. The most common grade ≥3 treatment-related AEs were thrombocytopenia (11%), pleural effusion (8%), and increased lipase (7%). AEs were attributed to death in 4 patients.

Patients with DLL3-high expression were more likely to experience treatment-related AEs compared with patients with DLL3-low expression (97% vs 69%, respectively), as well as AEs grade ≥3 (41% vs 23%). DLL3-high patients had a longer duration of treatment with Rova-T and longer follow-up.

An open-label phase 2 trial of Rova-T patients with relapsed or refractory SCLC whose cancer cells express a high level of DLL3, known as TRINITY, is currently underway.3 Results of this trial are expected in early 2018.

1. American Cancer Society. Key statistics for small cell lung cancer. Last revised January 4, 2018. Accessed January 29, 2018.
2. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42-51.
3. Study of rovalpituzumab tesirine (SC16LD6.5) for third-line and later treatment of subjects with relapsed or refractory delta-like protein 3-expressing small cell lung cancer (TRINITY). Accessed January 29, 2018.

Related Items
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing
TON Web Exclusives published on March 16, 2018 in Lung Cancer
FDA Grants Orphan Drug Designation to Seribantumab, an Investigational Treatment for Heregulin-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Three Leading Medical Societies Update Molecular Testing Guideline for Lung Cancer TKI Treatment
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Osimertinib Nearly Doubles PFS, Receives Breakthrough Therapy Designation in Frontline Treatment of EGFR-Positive NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Pembrolizumab, Pemetrexed, and Platinum Chemotherapy Combination Shows Improved OS and PFS in Patients with Metastatic Nonsquamous NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
FDA Approves Alectinib for ALK-Positive, Metastatic Non–Small-Cell Lung Cancer
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Last modified: January 29, 2018

©2019 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512